* Editas Medicine Inc is expected to show a fall in quarterly revenue when it reports results on May 3 (estimated) for the period ending March 31 2024
* The Cambridge Massachusetts-based company is expected to report a 19.8% decrease in revenue to $7.905 million from $9.85 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 67 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 3.2% in the last three months.
* Wall Street's median 12-month price target for Editas Medicine Inc is $15.50, above its last closing price of $5.21.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.60 -0.54 -0.23 Beat 57.6
Sep. 30 2023 -0.56 -0.57 -0.55 Beat 3.2
Jun. 30 2023 -0.76 -0.76 -0.56 Beat 26.6
Jan. 1 0001 -0.78 -0.78 -0.71 Beat 9.4
Dec. -0.80 -0.80 -0.88 Missed -9.7
31 2022
Sep. 30 2022 -0.83 -0.87 -0.81 Beat 6.8
Jun. 30 2022 -0.81 -0.82 -0.78 Beat 5.1
Mar. 31 2022 -0.78 -0.80 -0.74 Beat 6.9
This summary was machine generated May 1 at 13:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments